hydration benefits glp-1 receptor agonists Glucagon-like peptide-1 receptor: mechanisms and advances in therapy GLP-1 Receptor Agonists as Treatments

2026 ( Frontiers in Endocrinology ), Managing nausea and vomiting in GLP-1-based obesity therapies

doi: 10.2337/dc19-0760

Retatrutide 10mg is used to study its effects on weight loss, glucose control, and metabolic dysfunction in controlled laboratory settings, focusing on its triple GLP-1/GIP/Glucagon receptor agonist properties

The medication demonstrates substantial efficacy in reducing hemoglobin A1c levels and promoting weight loss, with reductions of up to 21% of body weight observed in clinical trials of patients with obesity without diabetes, and approximately 12-15% in those with type 2 diabetes

A retrospective disproportionality analysis was conducted using the reporting odds ratio (ROR) on FAERS data (20042024), with Bayesian confidence propagation neural network (BCPNN) employed for sensitivity analysis